News & Publications

Randomized Proof of Concept Trial of GLYX-13 in Major Depressive Disorder

Highlights the original Phase 2 proof-of-concept depression study with the first generation molecule in our class of NMDAR modulators. GLYX-13 reduced depressive symptoms within 2 hours of administration and the effect was maintained for 7 days on average, and the molecule did not elicit psychotomimetic or other significant side effects.

GLYX-13, a NMDA receptor partial agonist, induces antidepressant-like effects without ketamine-like side effects

Highlights the original discovery that our class of NMDA receptor modulators have pharmacology that exhibits efficacy in non-clinical models of depression.

1 2 3